An integrated Biobank in the Swedish Heart Failure Registry-clinomics, proteomics, transcriptomics and genomics.
Camilla Hage, Therese Andersson, Christina Christersson...
https://pubmed.ncbi.nlm.nih.gov/41961636Actively Recruiting
Age: 18Years +
All Genders
ID06435585
Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
Led by Karolinska University Hospital · Updated on 2024-05-30
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
K
Karolinska University Hospital
Lead Sponsor
U
University Hospital, Linkoeping
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying heart failure through the Swedish national heart failure quality registry called SwedeHF, which started in 2003. This registry is the largest continuous heart failure database globally, including over 140,000 entries from more than 110,000 patients across 70 hospitals in Sweden. The study aims to understand how genetic factors and various biomarkers relate to patients' responses to heart failure treatments and disease progression. University hospitals in Sweden with biobanking capabilities will collect blood plasma, whole blood, and urine samples linked to the SwedeHF registry. These samples allow detailed genetic, proteomic, and metabolomic analyses to identify new biomarkers and investigate differences between patients who respond or do not respond to guideline-directed medical therapy. The study will follow patients over 2 and 5 years to assess treatment response, morbidity, and mortality. Participants will be part of an observational study where their clinical data and biological samples are collected and analyzed. Researchers will measure outcomes such as treatment response, morbidity, and mortality over time. The study involves ongoing data entry into the SwedeHF registry and biobank sample collection. Participation includes consent and registration, with safety and ability to participate assessed by investigators. The study will continue until the end of 2030.
CONDITIONS
Brief Title
Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Written informed consent
- Diagnosed heart failure based on symptoms and signs as judged by a local doctor
- Registered in the Swedish heart failure quality registry SwedeHF
You will not qualify if you...
- Plasma donation within 1 month before joining or blood loss over 500 mL in the past 3 months
- Previous allogeneic bone marrow transplant
- Any condition that might risk safety, affect study results, or participation ability as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 5 years
Participants who are registered in the Swedish heart failure quality registry are observed to identify differences in morbidity and mortality over time and to study predictors of response to medical therapy.
Visits as part of routine clinical care; additional assessments may occur depending on participant status
Trial Site Locations
Total: 1 location
1
Karolinska University hospital
Stockholm, Sweden, 17164
Actively Recruiting
Loading map...
Research Team
C
Camilla Hage, Ass prof
U
Ulf Dahlström, Prof
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here